Randomized Trialhigh evidence
Economic Outcomes and Quality of Life After CABG or PCI for Multivessel Disease: The FAME 3 Trial.
Journal of the American College of Cardiology·April 28, 2026·PMID 41194756
Why it mattersThis trial provides contemporary evidence that FFR-guided PCI with modern drug-eluting stents offers equivalent quality of life at substantially lower cost than CABG for multivessel disease, challenging traditional assumptions about revascularization strategy value.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled